zimberelimab: Clinical Trials

6 trials of zimberelimab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 recruiting, 1 active not recruiting, 1 completed, 1 unknown. 6 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 36Recruiting 3, Active not recruiting 1, Completed 1, Unknown 1

Follow zimberelimab: new trials by email Literature Review of zimberelimab trials Research Report on zimberelimab

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer
Futibatinib, Zimberelimab, Durvalumab - Biliary Tract Cancer
Phase 3RecruitingTaiho Pharmaceutical Co., Ltd.7842026-06-242026-07-17
Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.
Zimberelimab, Sacituzumab govitecan, Cisplatin - Lung Diseases, Carcinoma, Non-Small-Cell Lung
Phase 3RecruitingFundación GECP1292025-02-042026-05-18
A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
GLS-010, Placebo, paclitaxel - Persistent, Recurrent, or Metastatic Cervical Cancer
Phase 3RecruitingGuangzhou Gloria Biosciences Co., Ltd.4242023-04-202026-09-16
A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body
Domvanalimab, Zimberelimab, Capecitabine - Advanced Upper Gastrointestinal Tract Adenocarcinoma
Phase 3CompletedArcus Biosciences, Inc.10402022-11-212026-09-03
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
Zimberelimab, Domvanalimab, Pembrolizumab - Non-small Cell Lung Cancer
Phase 3Active not recruitingGilead Sciences10212022-10-122026-01-30
GLS-010 Monotherapy Versus Chemotherapy in Patients With Relapsed or Refractory Classical Hodgkin's Lymphoma (R/R cHL)
GLS-010, Chemotherapy of Investigator's choice - Classic Hodgkin's Lymphoma, Recurrent Classic Hodgkin Lymphoma
Phase 3UnknownGuangzhou Gloria Biosciences Co., Ltd.602022-09-012022-08-26

Conditions studied

Carcinoma, Non-Small-Cell Lung (2)  ·  Recurrence (2)  ·  Acrocephalosyndactylia (1)  ·  Adenocarcinoma Of Esophagus (1)  ·  Biliary Tract Neoplasms (1)  ·  Lung Diseases (1)  ·  Parkinson Disease 4, Autosomal Dominant Lewy Body (1)  ·  Stomach Neoplasms (1)

Sponsors

Guangzhou Gloria Biosciences Co., Ltd. (2)  ·  Arcus Biosciences, Inc. (1)  ·  Fundación GECP (1)  ·  Gilead Sciences (1)  ·  Taiho Pharmaceutical Co., Ltd. (1)

Countries

China (3)  ·  Japan (3)  ·  South Korea (3)  ·  Spain (3)  ·  Argentina (2)  ·  Australia (2)  ·  Brazil (2)  ·  Canada (2)  ·  Chile (2)  ·  France (2)  ·  Hong Kong (2)  ·  Israel (2)  ·  Italy (2)  ·  Mexico (2)  ·  Portugal (2)

Top investigators

Mariano Provencio, MD (1)

Results publications

PMID 40341124

NIH funding

2023 (1)